Table 1 Baseline characteristics of participants
From: Long-term protection from naturally acquired immunity against hepatitis E virus reinfection
Total | Seropositive group | Seronegative group | P-value | |
|---|---|---|---|---|
Precise infection analysis (PI-A) set, n | 6369 | 2904 | 3465 | - |
Sex | <0.0001 | |||
Male, n (%) | 2567 (40.3%) | 1398 (48.1%) | 1169 (33.7%) | |
Female, n (%) | 3802 (59.7%) | 1506 (51.9%) | 2296 (66.3%) | |
Male-to-female ratio | 0.68 | 0.93 | 0.51 | |
Age, mean (SD) | 45.2 (10.8) | 46.7 (10.1) | 43.9 (11.3) | <0.0001 |
Overall infection analysis (OI-A) set, n | 6743 | 3076 | 3667 | - |
Sex | <0.0001 | |||
Male, n (%) | 2767 (41.0%) | 1500 (48.8%) | 1267 (34.6%) | |
Female, n (%) | 3976 (59.0%) | 1576 (51.2%) | 2400 (65.4%) | |
Male-to-female ratio | 0.70 | 0.95 | 0.53 | |
Age, mean (SD) | 44.9 (11.0) | 46.5 (10.3) | 43.5 (11.4) | <0.0001 |
Disease endpoint analysis (DE-A) set, n | 7032 | 3194 | 3838 | - |
Sex | <0.0001 | |||
Male, n (%) | 2938 (41.8%) | 1579 (49.4%) | 1359 (35.4%) | |
Female, n (%) | 4094 (58.2%) | 1615 (50.6%) | 2479 (64.6%) | |
Male-to-female ratio | 0.72 | 0.98 | 0.55 | |
Age, mean (SD) | 44.4 (11.3) | 46.2 (10.5) | 42.9 (11.8) | <0.0001 |
